Perla Breccia

Principal Scientist
Cambridge
UK

Perla Breccia PhD, is Chemistry leader for the CHDI ATM inhibitors programme and a Principal Scientist in medicinal chemistry at the Charles River Discovery Research Services site in Cambridge, UK. She has been involved in the CHDI collaboration since 2010 working previously at the HDAC class II inhibitors programme where she was involved in the design and synthesis of cyclopropane series targets for Huntington's disease.